499 related articles for article (PubMed ID: 21784898)
1. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.
Beck LH; Fervenza FC; Beck DM; Bonegio RG; Malik FA; Erickson SB; Cosio FG; Cattran DC; Salant DJ
J Am Soc Nephrol; 2011 Aug; 22(8):1543-50. PubMed ID: 21784898
[TBL] [Abstract][Full Text] [Related]
2. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
[TBL] [Abstract][Full Text] [Related]
3. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
4. Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy.
Cravedi P; Ruggenenti P; Remuzzi G
J Am Soc Nephrol; 2011 Aug; 22(8):1400-2. PubMed ID: 21784892
[No Abstract] [Full Text] [Related]
5. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA
Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329
[TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of Patients With Refractory PLA
Klomjit N; Fervenza FC; Zand L
Am J Kidney Dis; 2020 Dec; 76(6):883-888. PubMed ID: 32311405
[TBL] [Abstract][Full Text] [Related]
7. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
[TBL] [Abstract][Full Text] [Related]
8. Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.
Hofstra JM; Beck LH; Beck DM; Wetzels JF; Salant DJ
Clin J Am Soc Nephrol; 2011 Jun; 6(6):1286-91. PubMed ID: 21474589
[TBL] [Abstract][Full Text] [Related]
9. Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.
Brenchley PE
J Am Soc Nephrol; 2015 Oct; 26(10):2308-11. PubMed ID: 25804283
[No Abstract] [Full Text] [Related]
10. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1883-90. PubMed ID: 25267554
[TBL] [Abstract][Full Text] [Related]
11. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I
Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972
[TBL] [Abstract][Full Text] [Related]
12. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.
Beck LH; Bonegio RG; Lambeau G; Beck DM; Powell DW; Cummins TD; Klein JB; Salant DJ
N Engl J Med; 2009 Jul; 361(1):11-21. PubMed ID: 19571279
[TBL] [Abstract][Full Text] [Related]
13. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.
Dahan K; Johannet C; Esteve E; Plaisier E; Debiec H; Ronco P
Kidney Int; 2019 Jan; 95(1):233-234. PubMed ID: 30606419
[No Abstract] [Full Text] [Related]
14. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
Front Immunol; 2021; 12():738788. PubMed ID: 34721403
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
[TBL] [Abstract][Full Text] [Related]
16. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.
Irazabal MV; Eirin A; Lieske J; Beck LH; Sethi S; Borland TM; Dillon JJ; Nachman PH; Nasr SH; Cornell LD; Leung N; Cattran DC; Fervenza FC
Nephrol Dial Transplant; 2013 Jan; 28(1):137-46. PubMed ID: 22987142
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.
Zhou K; Zhou J; Zhou L; Xue J; Liu B; Zhang Z; Zhang X; Cai T; Shao S; Huang B; Zhang Y; Hu Z; Wang L; Liu X
PLoS One; 2024; 19(5):e0302100. PubMed ID: 38718066
[TBL] [Abstract][Full Text] [Related]
18. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
Ishiwatari A; Wakai S; Shirakawa H; Honda K
Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
[TBL] [Abstract][Full Text] [Related]
19. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
[No Abstract] [Full Text] [Related]
20. Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report.
Al-Rabadi L; Ayalon R; Bonegio RG; Ballard JE; Fujii AM; Henderson JM; Salant DJ; Beck LH
Am J Kidney Dis; 2016 May; 67(5):775-8. PubMed ID: 26744127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
